Simon Hsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simon Hsu has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Andrew N. Hoofnagle
Department of Laboratory Medicine & Pathology, University of Washington , Seattle, WA
10 shared publications - Ian H. de Boer
University of Washington
9 shared publications - Leila R. Zelnick
University of Washington
7 shared publications Ian H de Boer
Department of Medicine, Kidney Research Institute, University of Washington , Seattle, WA 98104
6 shared publications- Cora M. Best
Division of Nutritional Sciences; Cornell University; Ithaca NY USA
5 shared publications Andrew N Hoofnagle
Department of Medicine, Kidney Research Institute, University of Washington , Seattle, WA 98104
4 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (11)
Albuminuria, glomerular filtration rate, and fracture among U.S. adults with and without type 2 diabetes
CKD and type 2 diabetes (T2D) are established risk factors for fracture. Albuminuria and reduced estimated glomerular filtration rate (eGFR), the most commonly used measures to diagnose CKD, may confer fracture risk through distinct mechanisms. Clarifying the associations of albuminuria, reduced eGFR, and T2D status with fracture risk and potential interactions between these exposures may improve fracture risk assessment. We performed a cross-sectional study of 20 034 participants 50 yr or older in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2020. Albuminuria was defined by spot urine albumin-to-creatinine ratio ≥30 mg/g; reduced eGFR was defined as <60 mL/min/1.73 m2. Outcomes were prevalent hip and any fracture—the composite of any hip, wrist, or spine fracture—ascertained using self-report of physician diagnosis. Mean age was 63 yr; 53% were female, 9% were non-Hispanic Black, and 5% were Mexican–American. Participants reported 417 hip and 2703 any fractures. After adjusting for demographic and clinical covariates, including osteoporosis diagnosis and treatment, albuminuria was associated with increased odds of hip fracture (OR 1.59, 95% CI: 1.13-2.22), with no significant interaction by eGFR or T2D status. Neither reduced eGFR (OR 1.02; 95% CI: 0.73-1.44) nor T2D status (OR 0.94; 95% CI: 0.63-1.39) was associated with higher odds of hip fracture. Albuminuria, reduced eGFR, and T2D were not significantly associated with any fracture. In a subset of 7005 participants with BMD measurements, additional adjustment for FN BMD partially attenuated the association of albuminuria with hip fracture (OR 1.35; 95% CI: 0.72-2.53). In conclusion, albuminuria is associated with hip fracture in adults with and without T2D, independent of eGFR.
- 30 September 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (11)
Open AccessAlbuminuria, glomerular filtration rate, and fracture among U.S. adults with and without type 2 diabetes
CKD and type 2 diabetes (T2D) are established risk factors for fracture. Albuminuria and reduced estimated glomerular filtration rate (eGFR), the most commonly used measures to diagnose CKD, may confer fracture risk through distinct mechanisms. Clarifying the associations of albuminuria, reduced eGFR, and T2D status with fracture risk and potential interactions between these exposures may improve fracture risk assessment. We performed a cross-sectional study of 20 034 participants 50 yr or older in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2020. Albuminuria was defined by spot urine albumin-to-creatinine ratio ≥30 mg/g; reduced eGFR was defined as <60 mL/min/1.73 m2. Outcomes were prevalent hip and any fracture—the composite of any hip, wrist, or spine fracture—ascertained using self-report of physician diagnosis. Mean age was 63 yr; 53% were female, 9% were non-Hispanic Black, and 5% were Mexican–American. Participants reported 417 hip and 2703 any fractures. After adjusting for demographic and clinical covariates, including osteoporosis diagnosis and treatment, albuminuria was associated with increased odds of hip fracture (OR 1.59, 95% CI: 1.13-2.22), with no significant interaction by eGFR or T2D status. Neither reduced eGFR (OR 1.02; 95% CI: 0.73-1.44) nor T2D status (OR 0.94; 95% CI: 0.63-1.39) was associated with higher odds of hip fracture. Albuminuria, reduced eGFR, and T2D were not significantly associated with any fracture. In a subset of 7005 participants with BMD measurements, additional adjustment for FN BMD partially attenuated the association of albuminuria with hip fracture (OR 1.35; 95% CI: 0.72-2.53). In conclusion, albuminuria is associated with hip fracture in adults with and without T2D, independent of eGFR.
- 1 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (9) , 1584-1592
Prospective Cohort Study Evaluating Impact of Hemodialysis on Glycemia
Background: Hemodialysis affects glycemia in a manner that remains incompletely defined. Methods: In a prospective cohort study, 342 participants on maintenance hemodialysis wore a Dexcom G6 Pro continuous glucose monitor (CGM) for 10 days while dialyzing with standardized 100 mg/dL glucose dialysate. We examined glycemia relative to dialysis timing and tested associations of glycemia patterns with clinical characteristics and markers of overall glycemic control. Glucoregulatory hormones were measured pre- and post-dialysis in a subset of 20 participants. Results: Overall, CGM captured 1,001 hemodialysis sessions. Among participants with treated diabetes (n=143), untreated diabetes (n=78), and without diabetes (n=121), pre-dialysis glucose averaged 212 ± 84 mg/dL, 167 ± 65 mg/dL, and 120 ± 28 mg/dL, respectively. During dialysis, glucose declined by 53 ± 79 mg/dL, 29 ± 55 mg/dL, and 7 ± 32 mg/dL, respectively. Post-dialysis, glucose rebounded by 115 ± 70 mg/dL (to mean peak 265 ± 84 mg/dL), 95 ± 60 mg/dL (227 ± 71 mg/dL) and 61 ± 35 mg/dL (168 ± 37 mg/dL), respectively, with mean time to peak occurring later in treated (172 minutes post-dialysis) and untreated (169 min) diabetes compared with no diabetes (140 min). Post-dialytic rebound glycemia correlated with hemoglobin A1c and mean CGM glucose over the full observation period. Hypoglycemic events <70 mg/dL were uncommon (N=259); hypoglycemic event rates were significantly higher in the post-dialysis period compared with time-matched periods on non-dialysis days. There were no significant differences in hypoglycemic event rates pre- versus post-dialysis on dialysis days. In the substudy, most glucoregulatory peptides declined significantly (p<0.001) during dialysis including insulin (median change: -38%), glucagon (-43%), and glucagon-like peptide-1 (-38%). Conclusions: Hemodialysis induces intradialytic glucose declines and post-dialytic rebound that link to overall glycemic control, highlighting dialysis as a physiologic stressor on glucose homeostasis.
- 1 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (9) , 1584-1592
Prospective Cohort Study Evaluating Impact of Hemodialysis on Glycemia
Background: Hemodialysis affects glycemia in a manner that remains incompletely defined. Methods: In a prospective cohort study, 342 participants on maintenance hemodialysis wore a Dexcom G6 Pro continuous glucose monitor (CGM) for 10 days while dialyzing with standardized 100 mg/dL glucose dialysate. We examined glycemia relative to dialysis timing and tested associations of glycemia patterns with clinical characteristics and markers of overall glycemic control. Glucoregulatory hormones were measured pre- and post-dialysis in a subset of 20 participants. Results: Overall, CGM captured 1,001 hemodialysis sessions. Among participants with treated diabetes (n=143), untreated diabetes (n=78), and without diabetes (n=121), pre-dialysis glucose averaged 212 ± 84 mg/dL, 167 ± 65 mg/dL, and 120 ± 28 mg/dL, respectively. During dialysis, glucose declined by 53 ± 79 mg/dL, 29 ± 55 mg/dL, and 7 ± 32 mg/dL, respectively. Post-dialysis, glucose rebounded by 115 ± 70 mg/dL (to mean peak 265 ± 84 mg/dL), 95 ± 60 mg/dL (227 ± 71 mg/dL) and 61 ± 35 mg/dL (168 ± 37 mg/dL), respectively, with mean time to peak occurring later in treated (172 minutes post-dialysis) and untreated (169 min) diabetes compared with no diabetes (140 min). Post-dialytic rebound glycemia correlated with hemoglobin A1c and mean CGM glucose over the full observation period. Hypoglycemic events <70 mg/dL were uncommon (N=259); hypoglycemic event rates were significantly higher in the post-dialysis period compared with time-matched periods on non-dialysis days. There were no significant differences in hypoglycemic event rates pre- versus post-dialysis on dialysis days. In the substudy, most glucoregulatory peptides declined significantly (p<0.001) during dialysis including insulin (median change: -38%), glucagon (-43%), and glucagon-like peptide-1 (-38%). Conclusions: Hemodialysis induces intradialytic glucose declines and post-dialytic rebound that link to overall glycemic control, highlighting dialysis as a physiologic stressor on glucose homeostasis.
- 21 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1798-1810
Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis
Key Points: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. Background: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. Methods: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. Conclusions: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.
- 21 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1798-1810
Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis
Key Points: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. Background: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. Methods: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. Conclusions: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.
- 16 January 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (10) , 2903-2914
Genetic Variants Associated With the Biochemical Response to Vitamin D3 in the Multi-Ethnic Study of Atherosclerosis
Context: The response to treatment with vitamin D varies between patients. Objective: To identify genetic variants associated with the biochemical response to vitamin D3 supplementation. Design: Randomized placebo-controlled trial conducted between 2017 and 2019. Setting: The trial was nested in an ongoing community-based cohort study, the Multi-Ethnic Study of Atherosclerosis. Intervention: 2000 International Units of vitamin D3 or placebo daily for 16 weeks. Participants: The analytic sample included 427 participants assigned to vitamin D3 (mean age, 73 years; 54% females) and was 36% White, 33% Black, 18% Hispanic, and 14% Chinese. Main Outcome Measures: The biochemical response to vitamin D3 included changes in serum concentrations of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], PTH, and 25-hydroxyvitamin D3 [25(OH)D3]. Results: In genome-wide analyses, single nucleotide polymorphisms in 8 regions of the genome had significant association (P < 5E-08) with 1 of the traits (2 with change in 1,25(OH)2D3, 1 with change in PTH, and 5 with change in 25(OH)D3). rs16867276 within an intergenic region on 2q31 was associated with change in serum 1,25(OH)2D3 (+8.37 pg/mL difference per effect allele; P = 4.93E-08) and was the only locus that achieved genome-wide significance in transethnic meta-analysis. rs114044709 adjacent to FAM20A, which encodes a protein required for biomineralization, was associated with change in PTH among Black participants (+20.32 pg/mL difference per effect allele; P = 1.34E-08). In candidate analyses, single nucleotide polymorphisms within SULT2A1 and CYP24A1 had significant association (P < .05÷36 = .0014) with the changes in 1,25(OH)2D3 and PTH, respectively. Conclusion: Our results reveal potential new pathways of vitamin D regulation that require replication in other vitamin D trials.
- 16 January 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (10) , 2903-2914
Genetic Variants Associated With the Biochemical Response to Vitamin D3 in the Multi-Ethnic Study of Atherosclerosis
Context: The response to treatment with vitamin D varies between patients. Objective: To identify genetic variants associated with the biochemical response to vitamin D3 supplementation. Design: Randomized placebo-controlled trial conducted between 2017 and 2019. Setting: The trial was nested in an ongoing community-based cohort study, the Multi-Ethnic Study of Atherosclerosis. Intervention: 2000 International Units of vitamin D3 or placebo daily for 16 weeks. Participants: The analytic sample included 427 participants assigned to vitamin D3 (mean age, 73 years; 54% females) and was 36% White, 33% Black, 18% Hispanic, and 14% Chinese. Main Outcome Measures: The biochemical response to vitamin D3 included changes in serum concentrations of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], PTH, and 25-hydroxyvitamin D3 [25(OH)D3]. Results: In genome-wide analyses, single nucleotide polymorphisms in 8 regions of the genome had significant association (P < 5E-08) with 1 of the traits (2 with change in 1,25(OH)2D3, 1 with change in PTH, and 5 with change in 25(OH)D3). rs16867276 within an intergenic region on 2q31 was associated with change in serum 1,25(OH)2D3 (+8.37 pg/mL difference per effect allele; P = 4.93E-08) and was the only locus that achieved genome-wide significance in transethnic meta-analysis. rs114044709 adjacent to FAM20A, which encodes a protein required for biomineralization, was associated with change in PTH among Black participants (+20.32 pg/mL difference per effect allele; P = 1.34E-08). In candidate analyses, single nucleotide polymorphisms within SULT2A1 and CYP24A1 had significant association (P < .05÷36 = .0014) with the changes in 1,25(OH)2D3 and PTH, respectively. Conclusion: Our results reveal potential new pathways of vitamin D regulation that require replication in other vitamin D trials.
- Open Access
- 4 February 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (4) , 433-442
Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study
Fracture risk is high in chronic kidney disease (CKD) and underlying pathophysiology and risk factors may differ from the general population. In a cohort study of 3939 participants in the Chronic Renal Insufficiency Cohort (CRIC), we used Cox regression to test associations of putative risk factors with the composite of first hip or vertebral fracture assessed using hospital discharge codes. Mean age was 58 years, 45% were female, 42% were Black, and 13% were Hispanic. There were 82 hip and 24 vertebral fractures over a mean (SD) 11.1 (4.8) years (2.4 events per 1000 person-years [95% CI: 2.0, 2.9]). Measured at baseline, diabetes, lower body mass index (BMI), steroid use, proteinuria, and elevated parathyroid hormone (PTH) were each associated with fracture risk after adjusting for covariates. Lower time-updated estimated glomerular filtration rate (eGFR) was associated with fractures (HR 1.20 per 10 mL/min/1.73m2 lower eGFR; 95% CI: 1.04, 1.38) as were lower time-updated serum calcium and bicarbonate concentrations. Among time-updated categories of kidney function, hazard ratios (95% CI) for incident fracture were 4.53 (1.77, 11.60) for kidney failure treated with dialysis and 2.48 (0.86, 7.14) for post-kidney transplantation, compared with eGFR ≥60. Proton pump inhibitor use, dietary calcium intake, measures of vitamin D status, serum phosphate, urine calcium and phosphate, and plasma fibroblast growth factor-23 were not associated with fracture risk. In conclusion, lower eGFR in CKD is associated with higher fracture risk, which was highest in kidney failure. Diabetes, lower BMI, steroid use, proteinuria, higher serum concentrations of PTH, and lower calcium and bicarbonate concentrations were associated with fractures and may be modifiable risk factors.
- 4 February 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (4) , 433-442
Open AccessRisk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study
Fracture risk is high in chronic kidney disease (CKD) and underlying pathophysiology and risk factors may differ from the general population. In a cohort study of 3939 participants in the Chronic Renal Insufficiency Cohort (CRIC), we used Cox regression to test associations of putative risk factors with the composite of first hip or vertebral fracture assessed using hospital discharge codes. Mean age was 58 years, 45% were female, 42% were Black, and 13% were Hispanic. There were 82 hip and 24 vertebral fractures over a mean (SD) 11.1 (4.8) years (2.4 events per 1000 person-years [95% CI: 2.0, 2.9]). Measured at baseline, diabetes, lower body mass index (BMI), steroid use, proteinuria, and elevated parathyroid hormone (PTH) were each associated with fracture risk after adjusting for covariates. Lower time-updated estimated glomerular filtration rate (eGFR) was associated with fractures (HR 1.20 per 10 mL/min/1.73m2 lower eGFR; 95% CI: 1.04, 1.38) as were lower time-updated serum calcium and bicarbonate concentrations. Among time-updated categories of kidney function, hazard ratios (95% CI) for incident fracture were 4.53 (1.77, 11.60) for kidney failure treated with dialysis and 2.48 (0.86, 7.14) for post-kidney transplantation, compared with eGFR ≥60. Proton pump inhibitor use, dietary calcium intake, measures of vitamin D status, serum phosphate, urine calcium and phosphate, and plasma fibroblast growth factor-23 were not associated with fracture risk. In conclusion, lower eGFR in CKD is associated with higher fracture risk, which was highest in kidney failure. Diabetes, lower BMI, steroid use, proteinuria, higher serum concentrations of PTH, and lower calcium and bicarbonate concentrations were associated with fractures and may be modifiable risk factors.
- 24 January 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (5) , 638-640
Effects of Vitamin D3 Supplementation on Incident Fractures by eGFR in VITAL
An abstract is unavailable. This article is available as a PDF only.
- 24 January 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (5) , 638-640
Effects of Vitamin D3 Supplementation on Incident Fractures by eGFR in VITAL
An abstract is unavailable. This article is available as a PDF only.
- 6 October 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , e513-e521
The Vitamin D Metabolite Ratio Is Associated With Volumetric Bone Density in Older Men
Context Serum 25-hydroxyvitamin D [25(OH)D] is the current marker of vitamin D adequacy, but its relationship with bone health has been inconsistent. The ratio of 24,25-dihydroxyvitamin D3 to 25(OH)D3 (vitamin D metabolite ratio or VMR) is a marker of vitamin D that has been associated with longitudinal changes in BMD and fracture risk. Objective High-resolution peripheral quantitative computed tomography (HR-pQCT) provides information on bone health beyond standard dual-energy x-ray absorptiometry, in that it measures volumetric BMD (vBMD) as well bone strength. The relationship of the VMR with vBMD and bone strength remains unknown. Methods We evaluated the associations of the VMR and 25(OH)D3 with vBMD and bone strength, in the distal radius and tibia, assessed by HR-pQCT in 545 men participating in the Osteoporotic Fractures in Men (MrOS) Study. Primary outcomes were vBMD, as well as estimated failure load (EFL, a marker of bone strength), at the distal radius and tibia. Results The mean age was 84±4 years, 88.3% were White, and 32% had an estimated glomerular filtration rate 2. In adjusted models, each doubling of VMR was associated with a 9%(3%,16%) higher total vim and a 13%(5%,21%) higher EFL at the distal radius. Results were similar at the distal tibia. 25(OH)D3 concentrations were not associated with any of the studied outcomes. Conclusion Among older men, a higher VMR was associated with vBMD and bone strength while 25(OH)D3 was not. The VMR may serve as a valuable marker of skeletal health in older men.
- 6 October 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , e513-e521
The Vitamin D Metabolite Ratio Is Associated With Volumetric Bone Density in Older Men
Context Serum 25-hydroxyvitamin D [25(OH)D] is the current marker of vitamin D adequacy, but its relationship with bone health has been inconsistent. The ratio of 24,25-dihydroxyvitamin D3 to 25(OH)D3 (vitamin D metabolite ratio or VMR) is a marker of vitamin D that has been associated with longitudinal changes in BMD and fracture risk. Objective High-resolution peripheral quantitative computed tomography (HR-pQCT) provides information on bone health beyond standard dual-energy x-ray absorptiometry, in that it measures volumetric BMD (vBMD) as well bone strength. The relationship of the VMR with vBMD and bone strength remains unknown. Methods We evaluated the associations of the VMR and 25(OH)D3 with vBMD and bone strength, in the distal radius and tibia, assessed by HR-pQCT in 545 men participating in the Osteoporotic Fractures in Men (MrOS) Study. Primary outcomes were vBMD, as well as estimated failure load (EFL, a marker of bone strength), at the distal radius and tibia. Results The mean age was 84±4 years, 88.3% were White, and 32% had an estimated glomerular filtration rate 2. In adjusted models, each doubling of VMR was associated with a 9%(3%,16%) higher total vim and a 13%(5%,21%) higher EFL at the distal radius. Results were similar at the distal tibia. 25(OH)D3 concentrations were not associated with any of the studied outcomes. Conclusion Among older men, a higher VMR was associated with vBMD and bone strength while 25(OH)D3 was not. The VMR may serve as a valuable marker of skeletal health in older men.
- Open Access
- 18 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (14) , e028561
Vitamin D Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study
Background: The ratio of 24,25‐dihydroxyvitamin D 3 /25‐hydroxyvitamin D 3 (vitamin D metabolite ratio [VDMR]) may reflect functional vitamin D activity. We examined associations of the VDMR, 25‐hydroxyvitamin D (25[OH]D), and 1,25‐dihydroxyvitamin D (1,25[OH] 2 D) with cardiovascular disease (CVD) in patients with chronic kidney disease. Methods and Results: This study included longitudinal and cross‐sectional analyses of 1786 participants from the CRIC (Chronic Renal Insufficiency Cohort) Study. Serum 24,25‐dihydroxyvitamin D 3 , 25(OH)D, and 1,25(OH) 2 D were measured by liquid chromatography–tandem mass spectrometry 1 year after enrollment. The primary outcome was composite CVD (heart failure, myocardial infarction, stroke, and peripheral arterial disease). We used Cox regression with regression‐calibrated weights to test associations of the VDMR, 25(OH)D, and 1,25(OH) 2 D with incident CVD. We examined cross‐sectional associations of these metabolites with left ventricular mass index using linear regression. Analytic models adjusted for demographics, comorbidity, medications, estimated glomerular filtration rate, and proteinuria. The cohort was 42% non‐Hispanic White race and ethnicity, 42% non‐Hispanic Black race and ethnicity, and 12% Hispanic ethnicity. Mean age was 59 years, and 43% were women. Among 1066 participants without prevalent CVD, there were 298 composite first CVD events over a mean follow‐up of 8.6 years. Lower VDMR and 1,25(OH) 2 D were associated with incident CVD before, but not after, adjustment for estimated glomerular filtration rate and proteinuria (hazard ratio, 1.11 per 1 SD lower VDMR [95% CI, 0.95–1.31]). Only 25(OH)D was associated with left ventricular mass index after full covariate adjustment (0.6 g/m 2.7 per 10 ng/mL lower [95% CI, 0.0–1.3]). Conclusions: Despite modest associations of 25(OH)D with left ventricular mass index, 25(OH)D, the VDMR, and 1,25(OH) 2 D were not associated with incident CVD in chronic kidney disease.
- 18 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (14) , e028561
Open AccessVitamin D Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study
Background: The ratio of 24,25‐dihydroxyvitamin D 3 /25‐hydroxyvitamin D 3 (vitamin D metabolite ratio [VDMR]) may reflect functional vitamin D activity. We examined associations of the VDMR, 25‐hydroxyvitamin D (25[OH]D), and 1,25‐dihydroxyvitamin D (1,25[OH] 2 D) with cardiovascular disease (CVD) in patients with chronic kidney disease. Methods and Results: This study included longitudinal and cross‐sectional analyses of 1786 participants from the CRIC (Chronic Renal Insufficiency Cohort) Study. Serum 24,25‐dihydroxyvitamin D 3 , 25(OH)D, and 1,25(OH) 2 D were measured by liquid chromatography–tandem mass spectrometry 1 year after enrollment. The primary outcome was composite CVD (heart failure, myocardial infarction, stroke, and peripheral arterial disease). We used Cox regression with regression‐calibrated weights to test associations of the VDMR, 25(OH)D, and 1,25(OH) 2 D with incident CVD. We examined cross‐sectional associations of these metabolites with left ventricular mass index using linear regression. Analytic models adjusted for demographics, comorbidity, medications, estimated glomerular filtration rate, and proteinuria. The cohort was 42% non‐Hispanic White race and ethnicity, 42% non‐Hispanic Black race and ethnicity, and 12% Hispanic ethnicity. Mean age was 59 years, and 43% were women. Among 1066 participants without prevalent CVD, there were 298 composite first CVD events over a mean follow‐up of 8.6 years. Lower VDMR and 1,25(OH) 2 D were associated with incident CVD before, but not after, adjustment for estimated glomerular filtration rate and proteinuria (hazard ratio, 1.11 per 1 SD lower VDMR [95% CI, 0.95–1.31]). Only 25(OH)D was associated with left ventricular mass index after full covariate adjustment (0.6 g/m 2.7 per 10 ng/mL lower [95% CI, 0.0–1.3]). Conclusions: Despite modest associations of 25(OH)D with left ventricular mass index, 25(OH)D, the VDMR, and 1,25(OH) 2 D were not associated with incident CVD in chronic kidney disease.
- 20 May 2023
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 232, 106332
Metabolism and pharmacokinetics of vitamin D in patients with cystic fibrosis
- 20 May 2023
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 232, 106332
Metabolism and pharmacokinetics of vitamin D in patients with cystic fibrosis
- 1 March 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (3) , 287-289
Vitamin D Metabolite Ratio and Coronary Artery Calcification in the Multi-Ethnic Study of Atherosclerosis
- 1 March 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (3) , 287-289
Vitamin D Metabolite Ratio and Coronary Artery Calcification in the Multi-Ethnic Study of Atherosclerosis